Por: ABC News Business April 27, 2023
Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue. Soaring sales of the drugmaker’s top seller, the cancer treatment Keytruda, helped counter those hits, a drop expected by analysts.Merck said Thursday that sales of the COVID-19 treatment Lagevrio sank 88% in the quarter to $392 million. Lagevrio and Pfizer’s Paxlovid debuted well over a year... + full article
Associated Press USA Business April 27, 2023
Merck beat first-quarter expectations and hiked its 2023 forecast even as sales plunged for its COVID-19 treatment and a strong dollar hurt revenue. Soaring sales of the drugmaker’s top seller, the cancer treatment Keytruda, helped counter those hits, a drop expected by... + más
Merck Tops Quarterly Profit Estimates but Sees Weaker 2023 Revenue on Lagevrio Sales Drop | MarketWatch
Merck has strong quarter even as COVID-19 treatment tumble | ABC News
Associated Press USA Health February 24, 2023
A European medical committee recommends rejection of Merck’s COVID-19 treatment, Lagevrio, casting fresh doubt on a pill that also stirs concern among U.S. regulators.A European Medicines Agency committee says marketing authorization for the antiviral pill for use in the... + más
Moderna, Merck announce progress in vaccine against skin cancer to significantly boost survival rate | ABC7
MarketWatch USA Business February 02, 2023
The company is expecting revenue to drop in 2023 amid a decline in sales of Lagevrio, its Covid-19 antiviral, and on Thursday set earnings guidance that was well below Wall Street expectations. Still, Merck Chief Financial Officer Caroline Litchfield said that the company’s... + más
Merck, Moderna detail potential skin cancer vaccine progress | WPLG Local 10
Merck, Moderna detail potential skin cancer vaccine progress | ABC News
ABC News USA Business December 14, 2022
Moderna’s stock soared Tuesday after the COVID-19 vaccine maker detailed progress in developing a preventive shot for a deadly form of skin cancer.The company said a possible melanoma vaccine it is studying with pharmaceutical giant Merck fared well in a small study of... + más
Merck, Moderna detail potential skin cancer vaccine progress | Associated Press
ABC News USA Health December 14, 2022
WPLG Local 10 USA Health December 13, 2022
Associated Press USA Health December 13, 2022
About iurex | Privacy Policy | Disclaimer |